Paul Howley
49Patents
15h-index
13Co-inventors
74Inventor score
Filing activity: Jul 2, 2002 → Aug 18, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6761893B2 | Modified vaccinia ankara virus variant | Chemistry; Metallurgy | 96 | Expired |
| US6913752B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 40 | Expired |
| US7550147B2 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) | Emerging Cross-Sectional Technologies | 36 | Expired |
| US7189536B2 | Modified vaccinia ankara virus variant | Chemistry; Metallurgy | 28 | Expired |
| US7445924B2 | Modified Vaccinia Ankara virus variant and cultivation method | Chemistry; Metallurgy | 27 | Expired |
| US7384644B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 26 | Expired |
| US7335364B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 24 | Active |
| US7459270B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 18 | Active |
| US8309098B2 | Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs) | Emerging Cross-Sectional Technologies | 18 | Active |
| US7501127B2 | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara | Emerging Cross-Sectional Technologies | 17 | Active |
| US8021669B2 | Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) | Emerging Cross-Sectional Technologies | 15 | Active |
| US7964398B2 | Modified vaccinia ankara virus variant and cultivation method | Chemistry; Metallurgy | 15 | Active |
| US7964395B2 | Modified vaccinia ankara virus variant and cultivation method | Chemistry; Metallurgy | 15 | Active |
| US7923017B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 15 | Active |
| US7964396B2 | Modified vaccinia ankara virus variant and cultivation method | Chemistry; Metallurgy | 15 | Active |
| US7939086B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 15 | Active |
| US8268329B2 | Modified Vaccinia ankara virus variant | Chemistry; Metallurgy | 14 | Active |
| US8236560B2 | Modified Vaccinia Ankara virus variant and cultivation method | Chemistry; Metallurgy | 13 | Active |
| US8470598B2 | Modified Vaccinia Ankara virus variant and cultivation method | Chemistry; Metallurgy | 12 | Active |
| US6924137B2 | Method for virus propagation | Chemistry; Metallurgy | 12 | Expired |
| US8268325B2 | Modified Vaccinia Ankara virus variant | Chemistry; Metallurgy | 11 | Active |
| US7569228B2 | Fusion proteins of non-attenuated HIV regulatory/accessory proteins | Chemistry; Metallurgy | 10 | Active |
| US8029800B2 | Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs) | Emerging Cross-Sectional Technologies | 9 | Active |
| US8435543B2 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) | Emerging Cross-Sectional Technologies | 7 | Active |
| US8034354B2 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) | Emerging Cross-Sectional Technologies | 7 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.